Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2019-04-25 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
关于使用部分闲置募集资金购买的理财产品提前支取并继续进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the use of idle raised funds to purchase financial products, including details of early redemption and continued cash management. It includes specifics about investment amounts, dates, and risk control measures. The document references prior shareholder meeting approvals and discloses ongoing compliance with regulatory requirements. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about the company's capital management activities related to raised funds. The document length is about 5000 characters, and it is a detailed announcement rather than a brief notice or a report publication announcement. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including the use of raised funds and related financial product investments.
2019-04-25 Chinese
关于使用募集资金增资全资子公司实施募投项目的进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding the use of raised funds to increase capital in a wholly-owned subsidiary for project implementation. It details specific capital injections, dates, and changes in registered capital. The document is relatively short (1007 characters) and focuses on updates about capital use and project progress rather than presenting full financial statements or comprehensive financial performance. It is not an annual or interim report, nor an earnings release. It is an update on financing activities related to capital injection using raised funds, which fits the Capital/Financing Update category.
2019-04-25 Chinese
关于使用部分闲置募集资金购买保本型理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding the use of part of its idle raised funds to purchase principal-guaranteed financial products. It details the approval by the board, the amount of funds raised through a non-public stock issuance, the intended investment projects, the current usage and idle status of the raised funds, and the decision to invest up to 200 million RMB of idle funds in low-risk financial products. It includes opinions from independent directors, the supervisory board, and the sponsoring institution, confirming compliance with regulatory requirements and no adverse impact on the original investment plans. The document is a formal disclosure about the company's capital management and investment of idle raised funds, not a financial report or earnings release. It is not a full annual or interim report, nor a call transcript or management report. It is a capital/financing update related to the use of raised funds and their investment in financial products. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains detailed information about the financing and fund usage, not just an announcement of a report or certification, so it is not RPA or RNS.
2019-04-19 Chinese
独立董事2018年度述职报告（刘俊峰）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2018 Annual Report" and details the independent director's activities, attendance at board and shareholder meetings, opinions on various board resolutions, training, and oversight of company governance and investor protection during the 2018 fiscal year. It is a narrative report on the independent director's duties and observations rather than a financial report or regulatory filing. The document length is 3361 characters, which is relatively short but contains substantive content about the director's role and opinions rather than just an announcement or certification. This type of document fits best under Board/Management Information (MANG), as it relates to the independent director's report on their management oversight and governance role.
2019-04-19 Chinese
2018年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2018 年年度报告摘要" which translates to "2018 Annual Report Summary". It contains detailed financial data for the year 2018, including revenue, net profit, earnings per share, and other financial metrics. It also discusses company business operations, industry conditions, accounting policy changes, and corporate structure. The length of the document (11,810 characters) and the presence of substantive financial data and analysis confirm it is a full financial report rather than a brief announcement or summary. The content aligns with the definition of an Annual Report (10-K) which covers company activity and full financial performance for the fiscal year. Therefore, the document should be classified as an Annual Report (10-K). FY 2018
2019-04-19 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It references auditing standards and responsibilities related to internal control over financial reporting as of December 31, 2018. The document contains an auditor's opinion on the effectiveness of internal controls, signed by certified public accountants. It does not contain a full annual report or financial statements but is a standalone audit report focused on internal control effectiveness. This matches the definition of an Audit Report / Information (AR). The document length is short but contains substantive audit content, not just an announcement or certification letter. Therefore, it should be classified as AR. FY 2018
2019-04-19 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.